Allogene Therapeutics, Inc. (NASDAQ:ALLO) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: US$175M · US$2 a share · Goldman Sachs & Co. LLC +7 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Piper Sandler (co-lead), William Blair (co-lead), TPG Capital BD, LLC, Baird, Canaccord Genuity Use of proceeds: General corporate purposes, which may include clinical trial, R&D, G&A expenses and capital expenditures | Apr 14, 2026 |